vaborbactam (Vabomere) Report issue

Small molecule Approved FDA Fast Track FDA Priority Review FDA

Active Ingredient History

NOW
  • Now
Vaborbactam (formerly RPX7009) is a new beta-lactamase inhibitor based on a cyclic boronic acid pharmacophore. Vaborbactam is a highly active beta-lactamase inhibitor that restores activity of meropenem and other beta-lactam antibiotics in beta-lactamase-producing bacteria, particularly KPC-producing CRE. Meropenem in combination with vaborbactam (VABOMERE) is indicated for the treatment of patients 18 years and older with complicated urinary tract infections including pyelonephritis caused by designated susceptible bacteria. The vaborbactam component of VABOMERE is a non-suicidal beta-lactamase inhibitor that protects meropenem from degradation by certain serine beta-lactamases such as Klebsiella pneumoniae carbapenemase (KPC). Vaborbactam does not have any antibacterial activity. Vaborbactam does not decrease the activity of meropenem against meropenem-susceptible organisms.   NCATS

Chemistry

  • SMILES: O=C(O)C[C@@H]1CC[C@H](NC(=O)Cc2cccs2)B(O)O1
  • InChIKey: IOOWNWLVCOUUEX-WPRPVWTQSA-N
  • Mol. Mass: 297.14
  • ALogP: Missing data
  • ChEMBL Molecule:
    vaborbactam  
More Chemistry

Pharmacology

Combination drugs

( meropenem (merrem), vaborbactam (Vabomere) - other name: meropenem and vaborbactam )

Organizations (4)

Research & Development (2)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (2)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (3)

Approved Indications (1)


 

Urinary Tract Infections

Experimental Indications - Clinical Trial Phases 1-4 (2)


 

Healthy Volunteers (Phase 1)

Pneumonia (Phase 3)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 1
  • # of Trial Organizations: 2

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue